QUAY STEVEN C 4/A

What Happened
Steven C. Quay, President, CEO and Director of Atossa Therapeutics (ATOS), received equity awards on January 20, 2026. The filings show (1) 331,674 restricted stock units (RSUs) granted (reported at $0.00) and (2) 950,000 derivative awards reported at $0.60 each for a reported aggregate value of $572,850. These were grants/awards (not open-market purchases or sales).

Key Details

• Transaction date: January 20, 2026; Form 4 originally filed Jan 22, 2026 and amended Jan 30, 2026 to correct the RSU count.
• RSUs: 331,674 RSUs — each RSU is a contingent right to one share; vesting one year from the transaction date (Footnote F1).
• Derivative awards: 950,000 units reported at $0.60 each (total $572,850). Footnote F4 clarifies these are options that vest quarterly over 24 months and carry an exercise price of $0.603 (the Jan 20 closing price). These are grants, not exercised shares.
• Ownership after transaction: not specified in the excerpt of the filing provided.
• Reporting/Amendment: The Form 4 was amended to correct an administrative error regarding the number of RSUs (Footnote F2).
• Other note: Footnote F3 describes Ensisheim Partners, LLC (wholly owned by Mr. Quay and Dr. Shu‑Chih Chen) and the parties’ shared voting/investment power; Mr. Quay disclaims beneficial ownership of Ensisheim-held securities except to the extent of pecuniary interest.

Context

• RSUs are contingent grants that convert to shares only upon vesting (one-year cliff here), so they do not represent immediate share ownership or sale proceeds.
• The derivative awards are time‑based options (vesting over 24 months) with an exercise price equal to the reported closing price; these are typical retention/compensation grants rather than exercised or sold securities.
• The amendment appears administrative (correcting RSU count) rather than indicating a late initial filing with respect to the original Form 4.